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Interleukin-24 (IL-24) belongs to the IL-10 family of cytokines 
and is well known for its tumor suppressor activity. This cyto-
kine is released by both immune and nonimmune cells and 
acts on non-hematopoietic tissues such as skin, lung and re-
productive tissues. Apart from its ubiquitous tumor sup-
pressor function, IL-24 is also known to be involved in the im-
munopathology of autoimmune diseases like psoriasis and 
rheumatoid arthritis. Although the cellular sources and func-
tions of IL-24 are being increasingly investigated, the molec-
ular mechanisms of IL-24 gene expression at the levels of 
signal transduction, epigenetics and transcription factor 
binding are still unclear. Understanding the specific molec-
ular events that regulate the production of IL-24 will help to 
answer the remaining questions that are important for the 
design of new strategies of immune intervention involving 
IL-24. Herein, we briefly review the signaling pathways and 
transcription factors that facilitate, induce, or repress pro-




Interleukins are an integral part of our immune system and 
are often involved in stimulating or suppressing the immune 
system  and  inflammation.  They  are  mainly  produced  by  T 
lymphocytes, monocytes, macrophages, and endothelial cells. 
The induction and expression of interleukins require the coor-
dinated  action  of  lineage-restricted  complex  transcriptional 
networks. For example, IFN-γ, IL-4 and IL-10 have been ex-
tensively studied for their cellular sources, functions and the 
factors involved in regulation of their expression in response 
to  diverse  stimuli  (1-9).
    IL-24 was identified by subtraction hybridization of cDNA 
libraries from human melanoma cells and was initially named 
as melanoma differentiation associated gene 7 (MDA-7) (10). 
IL-24 is located in chromosome 1 along with IL-10, IL-19 and 
IL-20 and shares both structural and sequence homology (11). 
The cellular sources and functions of IL-24 have been a sub-
ject  of  active  research  and  have  been  well  documented  in 
published  reviews  (12-14).  However  a  few  recent  studies 
from our group and others have reported molecular mecha-
nisms directly related to IL-24 gene regulation in various cells. 
Here  we  concisely discuss the recent information  regarding 
the  signaling  pathways  and  transcription  factors  along  with 
chromatin remodeling and epigenetic events involved in the 
transcriptional  regulation  of  IL-24 g e n e  i n  t h e  r e p o r t e d  c e l l  
types.
CELLULAR SOURCES OF INTERLEUKIN-24
IL-24 is produced by various immune cells such as peripheral 
blood mononuclear cells (PBMC), preferably monocytes, and 
T  and  B  cells.  Antigenic  stimulations  by  concavalin  A,  lip-
opolysaccharide,  or  cytokines  induce  IL-24  expression  in 
monocytes  (15,16).  TCR  stimulation  aided  by  anti-CD3  and 
CD28 or PMA and Ionomycin also induce physiological levels 
of IL-24 in T helper 2 (Th2) lymphocytes (17,18). Similar to 
Th2 cells, B cell receptor signaling (anti-IgM plus CD40-L) al-
s o  t r i g g e r s  I L - 2 4  e x p r e s s i o n  i n  B  l y m p h o c y t e s  ( 1 9 ) .  A p a r t  
from these cells of the immune system, physiological levels 
of IL-24 is also produced by cells of non-lymphoid origin like Molecular Mechanisms Governing IL-24 Gene Expression
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cultured  melanocytes,  dermal keratinocytes, and IL-1 stimu-
lated  human  colonic  subepithelial  myofibroblasts  (SEMFs) 
(10,20,21). Although IL-24 expression is abundant in melano-
cytes, it is gradually lost during melanoma progression and 
is usually absent in various malignant melanoma and other 
cells. However IL-24 expression is revived in these cells upon 
treatment of IFN-β and mezerin which induce differentiation 
in  melanoma  cells  (10,22).  IL-1β stimulation  also  induces 
IL-24  expression  in  both  keratinocytes  and  SEMFs  (20).
FUNCTIONS OF INTERLEUKIN-24
The  secreted  IL-24  protein  interacts  in  a  paracrine  manner 
with IL-20R1/IL-20R2 and IL-22R1/IL-20R2 receptor complexes 
(23-25). Both these receptors are abundant in several tissues 
such as those from the reproductive and respiratory systems 
and  various glands making them  the main targets of IL-24. 
Keratinocytes express both the IL-24 receptor complexes and 
stimulation of normal human epidermal keratinocytes (NHEK) 
with IL-24 in vitro induces STAT3 activation which alters their 
differentiation, proliferation and induces the expression of a 
number of psoriasis-related genes. Taken together these find-
ings suggest a role for IL-24 in the pathogenesis of psoriasis 
and  other  inflammatory  conditions  in  the  skin  (21,26).  In-
crease in IL-24 expression has been seen at the edge of exci-
sional skin wounds, in the joints of rheumatoid arthritis pa-
tients and in active lesions from patients who have ulcerative 
colitis and Crohn’s disease (20,27,28). However the exact cell 
subsets  producing  IL-24  in  the  above  places  are  not  clear. 
    Most  immune  cells  lack  the  IL-20R1  or  IL-22R1  receptors 
but the IL-20R2 is expressed in these cells. Adenovirus medi-
ated ectopic expression of IL-24 can activate the IFN-γ and 
NFκ β pathways  and  also  induce  the  secretion  of  pro-Th1 
cytokines like IFN-γ, IL-6, TNF-α, IL1β, IL-12 and GM-CSF 
in human PBMCs favoring a Th1 type immune response (15). 
The  upregulated  IFN-γ  in  turn  can  further  up-regulate 
IL-22R1  expression  in  keratinocytes  and  a  formation  of 
IL-22R1/IL-20R2 complex promotes the innate immunity of tis-
sues (29). IL-24 also inhibits differentiation of germinal center 
B cells into mature plasma cells by coordinating multiple mo-
lecular events like downregulation of transcription factors like 
IRF4, Blimp1 and Bcl6 which play a crucial role in plasma 
cell  differentiation  (19).  Although  down-regulation  of  IRF4 
and Blimp1 could be directly involved in inhibition of plasma 
cell  differentiation,  the  role  of  Bcl6  in  this  matter  is  still 
unclear. Since Bcl6 facilitates expansion of the germinal cen-
tre B cells (30) and IL-24 blocks entry of the plasma cell pre-
cursors  into  the  cell  cycle,  down  regulated  Bcl6  by  IL-24 
could indirectly lead to plasma cell differentiation inhibition. 
However the exact effect of downregulated Bcl6 upon addi-
tion of IL-24 in the context of plasma cell differentiation in-
hibition  needs  further  scrutiny.  Analysis  of  IL-24  transgenic 
mice reveal a largely redundant role of IL-24 with IL-20 and 
IL-22 in epidermal functions (31). Unfortunately no published 
reports showing the phenotype of mice deficient of IL-24 are 
available, however mice deficient of the IL-20R2 shows that 
IL-24 along with IL-19 and IL-20 are part of a signaling net-
work  that  down-modulate  T  cell  responses  in  mice  (32).
    Although IL-24 is a cytokine produced by various immune 
cells, rather than its physiological role in the immune system, 
its  tumor  suppressor  role  has  been  well  documented. 
Mechanisms leading to cell death in human melanoma and 
various kinds of other cancer cell lines by adenovirus medi-
ated  overexpression  of  IL-24 have  been  extensively  studied 
and reviewed (13,14,33,34). Upregulation of endoplasmic re-
ticulum (ER) stress, activation of the p38 MAPK pathway and 
the  GADD  family  genes  leads  to  apoptosis  in  cancer  cells 
upon  adenoviral  expression  of  IL-24  (35-37).  IL-24  induces 
cancer cell specific oxidative stress by generation of reactive 
oxygen species (ROS) followed by mitochondrial dysfunction 
uniquely  in  cancer  cells  and  also  inhibits  angiogenesis,  in-
vasion  and  migration  of  cancer  cells  (38-42).  Ectopic  ex-
pression of IL-24 also induces IFN-γ and IL-6 secretion from 
melanoma cells having potent anti-tumor functions (12, 15). 
Administration  of  IL-24  via  adenoviral  vector  (Ad.MDA-7) 
generates  a  significant  increase  in  the  CD3＋CD8＋ pop-
ulation  thus  promoting  immune  activation,  leading  to  anti-
cancer immunity. Phase-I clinical trial in melanoma showed 
transient increases in circulating cytokines such as IL-6, IL-10 
and  TNF-α in  response  to  IL-24  and  a  significant  increase 
in CD3＋CD8＋ T cells suggesting that Ad.MDA-7 may be as-
sociated  with  a  Th1-like  response  (13,43,44).
TRANSCRIPTIONAL REGULATION OF 
INTERLEUKIN-24
Mutually  exclusive  patterns  of  cytokine  production  in  fully 
committed  CD4＋ or  CD8＋ T  lymphocytes  are  precisely 
regulated by diverse signaling pathways and transcription fac-
tors  upon  exposure  to  antigen  and  polarizing  cytokines  ex 
vivo. During this process, the differentiating cells undergo ex-
tensive changes in transcriptional activity, signature gene ex-Molecular Mechanisms Governing IL-24 Gene Expression
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pression  and  cell  specific  functions.  The  important  role  of 
chromatin remodeling and epigenetic regulation mechanisms 
for transcription of cytokine genes in mammalian cells have 
been also reported (45-51). Unlike its Th2 cell counterparts, 
the  molecular  mechanisms  governing  IL-24  production  are 
less well defined. As mentioned in the previous section, phys-
iological levels of IL-24 are produced by cells of both lym-
phoid and non-lymphoid lineages. However the factors and 
mechanisms  driving  the  differential  expression  of  IL-24  are 
not completely understood and have not been fully identified 
i n  a n y  c e l l  t y p e .
Non-immune cells
Initial  studies  in  the  beginning  of  the  last  decade  charac-
terized the functional promoter of the IL-24 gene for the first 
time in human melanoma (HO-1) cells. A study by Madireddi 
et al showed that reexpression of IL-24 in human melanoma 
cells upon treatment of differentiation inducers such as IFN-β 
and mezerin is dependent on the AP-1 family member c-Jun 
and the C/EBP family member C/EBP-β. Both these factors 
directly bind to the human IL-24 promoter and elevate IL-24 
expression by activating its promoter (52). According to an-
other  report  the  increased  IL-24  expression  during  terminal 
differentiation in human melanoma cells is also regulated at 
posttranscriptional level. The study showed that although the 
IL-24  promoter  is  active  and  IL-24  mRNA  is  actively  tran-
scribed  in  melanoma  cells,  the  3'  UTR  of  IL-24  containing 
AU-rich elements (ARE) makes the IL-24 mRNA unstable in 
these  cells  leading  to  gradual  decrease  in  IL-24  production 
upon melanoma progression. This message is stabilized upon 
treatment of differentiation inducers IFN-β and mezerin lead-
ing to reexpression of IL-24 in these cells (53). Although the 
above study suggested that mRNA stabilization is of major im-
portance  to  IL-24  expression,  the  pathways  responsible  for 
the regulation of IL-24 mRNA stability were not identified. A 
recent  report  showed  that  IL-1β stimulation  induced  IL-24 
expression in cultured normal human keratinocytes is strongly 
dependent on p38 MAPK activation. Inhibition of this path-
way accelerates IL-24 mRNA destabilization mediated by the 
3' UTR of IL-24 mRNA suggesting that p38 MAPK regulates 
IL-24 expression at the post transcriptional level (54). Apart 
from melanocytes and keratinocytes, IL-24 expression in the 
inflamed mucosa of patients with inflammatory bowel disease 
(IBD), was also reported and the molecular mechanisms re-
sponsible  for  its  expression  in  human  colonic  SEMFs  were 
identified.  Similar  to  differentiated  melanoma  (HO-1)  cells, 
AP-1 and C/EBP binding to the IL-24 promoter was reported 
i n  t h e s e  c e l l s  u p o n  I L - 1β stimulation  leading  to  enhanced 
IL-24  mRNA  and  protein  expression.  IL-1β also  led  to  in-
creased  IL-24  mRNA  stabilization  in  SEMFs  (20).
Immune cells
As mentioned previously, cells of the immune system are also 
major producers of IL-24. However similar to its nonimmune 
counterparts, reports about the signaling pathways and tran-
scription  factors  inducing  IL-24  expression  in  immune  cells 
are few. Schaefer et al. for the first time identified IL-24 in 
mouse  CD4＋ T  lymphocytes  and  designated  it  as  FISP 
(IL-4-induced secreted protein), which is selectively expressed 
and secreted by Th2 cells. Detectable levels of IL-24 (FISP) 
are observed only 3 days after initiation of Th2 differentiation 
and its expression requires at least two signals: TCR signaling 
involving protein kinase C (PKC) activation and Stat6-depen-
dent  IL-4R  signaling  (18).  Recently  our  group  further  de-
lineated the exact molecular mechanism responsible for this 
Th2 cell specific expression of IL-24. We identified the prox-
imal promoter region that confers Th2 cell specificity to the 
IL-24 gene. Our data also showed that the IL-24 promoter lo-
cus has an active chromatin configuration in Th2 cells upon 
TCR stimulation (17). Similar to human melanoma cells and 
SEMFs, the role of AP-1 family member c-Jun is predominant 
in regulating IL-24 expression in Th2 cells suggesting that reg-
ulation  of  the  IL-24  gene  is  conserved  in  mice  and  human 
and also across cell types. TCR signaling as well as mezerin 
which is a nonphorbol ester both activate PKC which further 
activates  the  AP-1  family  of  transcription  factors.  Stat6,  a 
member  of  the  STAT  family  of  proteins  which  acts  down-
stream of the IL-4 signaling pathway also binds to the IL-24 
promoter locus along with c-Jun and transactivate it. This in-
creased  binding  is  facilitated  by  the  accessible  chromatin 
structure and active histone marks evident by increased re-
cruitment  of  acetyl  histone  H3  lysine9/14 (H3AcK9/14)  and 
histone H3 lysine 4 methylation (H3K4Me2) at the IL-24 pro-
moter  in  Th2  cells  (17).  The  above  active  histone  mod-
ifications and open and accessible chromatin are usually asso-
ciated  with  the  promoters  of  actively  transcribed  genes 
(55-57). A report by Wei et al. also showed direct binding 
of Stat6 along with active chromatin configuration (H3k4me3 
and H3k36me3) at the IL-24 promoter. These modifications 
were shown to be Stat6 dependent, since Stat6 deficient mice 
showed decreased or less recruitment of the above proteins 
at the IL-24 promoter (58). The same locus however is occu-Molecular Mechanisms Governing IL-24 Gene Expression
Anupama Sahoo and Sin-Hyeog Im
4 IMMUNE NETWORK http://www.ksimm.or.kr Volume 12 Number 1 February 2012
pied by histone deacetylase (HDAC) 1 in Th1 cells. Our cur-
rent investigations reveal that this increased HDAC1 recruit-
ment to the IL-24 promoter is mediated by other repressive 
factor(s) like Ets-1 pre-bound to the IL-24 genomic locus spe-
cifically in the Th1 cells (unpublished data). Thus, chromatin 
remodeling may contribute to the cell-specific expression of 
IL-24, controlling the access of appropriate key transcription 
factors  and  the  transcriptional  machinery  to  the  promoter. 
Our unpublished studies also indicate the involvement of spe-
cific transcription factors and chromatin remodeling events in 
IL-24 expression in effector CD8
＋ T cells. IL-24 is also opti-
mally induced by B cell receptor triggering and CD40 engage-
ment  in  germinal  centre  B  cells  (19).  However  the  tran-
scription factors downstream of these pathways which aid in 
IL-24  production  in  B  lymphocytes  still  remain  to  be  iden-
tified.
EPIGENETIC REGULATION OF INTERLEUKIN-24 IN 
CANCER
Chromatin  remodeling  and  epigenetic  events  not  only  play 
an important role in regulating the lineage specific expression 
of IL-24 in Th2 cells but also it plays important role in cancer 
cells. A recent report showed that the expression of IL-24 was 
upregulated by the HDAC inhibitors trichostatin A (TSA) and 
sodium butyrate, whereas it was downregulated by HDAC4 
in human melanoma (A375) cells. The histone acetylation lev-
el and the binding of the transcriptional factor Sp1 to the hu-
man IL-24 promoter in these cells were reduced upon HDAC4 
overexpression  (59).  This  gradual  suppression  and  absence 
of  IL-24  expression  could  also  be  attributed  to  other  forms 
of epigenetic silencing, since no inactive mutation or struc-
tural rearrangements were identified in IL-24 in any type of 
cancer cell (60,61). Various studies have suggested that there 
is  direct  correlation  between  epigenetic  modifications,  such 
as histone methylation, histone acetylation, DNA methylation, 
and gene expression in disease-relevant cells, including can-
cer cells. Epigenetic inactivation of tumor suppressor genes 
or tumor related genes by hyper methylation in promoter re-
gion is a common event in human tumor cell lines and hu-
man cancer (62,63). The importance of epigenetic events in 
development and proper function of various normal cellular 
processes is also increasing attention. Our unpublished find-
ings show increased DNA methylation at the IL-24 promoter 
in Th1 cells compared to Th2 cells. Inhibition of DNA methyl-
transferases by treatment of 5'Azacytidine increases IL-24 pro-
duction not only in Th1 cells but also in a few types of cancer 
cells. Hence apart from identifying factors important to upre-
gulate IL-24 expression, understanding the molecular mecha-
nisms  underlying  IL-24  gene  silencing  could  be  of  great 
significance.
SUMMARY AND FUTURE PERSPECTIVES
Altogether  the  above  findings  suggest  that  IL-24  gene  tran-
scription requires the combined action of transcription factors, 
as well as active chromatin remodeling and epigenetic mod-
ifications in the IL-24 promoter locus in both normal cells and 
cancer cells. The effect of transcription factors and epigenetic 
modifications on the regulation of gene expression and the 
concomitant  relationship  to  human  diseases  has  become  a 
key area of biological research in the recent years. Explora-
tion of the basic events involved in altered gene transcription 
patterns and/or silencing of IL-24 in normal cells or cancer 
cells will also help in developing ways to pharmacologically 
alter  the  epigenetic  abnormalities  and  lL-24  expression.
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